Patents Assigned to ZymoGenetics
  • Appetite supression factor and related methods
    Patent number: 5858967
    Abstract: Methods for identifying factors that regulate appetite are disclosed. Preferably, the methods feature determinination of decreased food consumption in selected recipient mammals following administration of a test sample. A product having appetite suppressing activity is also described. In addition, methods for reducing food consumption in a mammal, featuring administration of a pharmaceutical composition comprising a representative appetite suppression factor, are disclosed.
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: January 12, 1999
    Assignees: University of Washington, Zymogenetics, Inc.
    Inventors: David S. Weigle, Joseph L. Kuijper, John W. Forstrom
  • Transformation of pichia methanolica
    Patent number: 5854039
    Abstract: Methods for transforming Pichia methanolica, and DNA molecules useful in transformation of P. methanolica, are disclosed. P. methanolica cells are exposed, in the presence of DNA molecules, to a pulsed electric field having a field strength of from 2.5 to 4.5 kV/cm and a pulse duration of from 1 to 40 milliseconds, whereby the DNA molecules are introduced into the cells. The DNA molecules may comprise an expression unit that includes a transcription promoter of a P. methanolica gene operably linked to a segment encoding a polypeptide or protein of interest. The DNA molecules may also encode a selectable marker, such as a P. methanolica ADE2 gene. Cells transformed according to the invention may be used in production systems for the preparation of proteins of commercial importance.
    Type: Grant
    Filed: July 14, 1997
    Date of Patent: December 29, 1998
    Assignee: ZymoGenetics, Inc.
    Inventors: Christopher K. Raymond, Susan D. Holderman, Erica Vanaja
  • Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
    Patent number: 5843725
    Abstract: Methods for producing secreted receptor analogs and biologically active peptide dimers are disclosed. The methods for producing secreted receptor analogs and biologically active peptide dimers utilize a DNA sequence encoding a receptor analog or a peptide requiring dimerization for biological activity joined to a dimerizing protein. The receptor analog includes a ligand-binding domain. Polypeptides comprising essentially the extracellular domain of a human PDGF receptor fused to dimerizing proteins, the portion being capable of binding human PDGF or an isoform thereof, are also disclosed. The polypeptides may be used within methods for determining the presence of and for purifying human PDGF or isoforms thereof.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 1, 1998
    Assignee: ZymoGenetics, Inc.
    Inventors: Andrzej Z. Sledziewski, Lillian Anne Bell, Wayne R. Kindsvogel
  • Cross-linked gelatin gels and methods of making them
    Patent number: 5834232
    Abstract: Enzymatically cross-linked protein gels and methods for preparing them are disclosed. The methods comprise adding a transglutaminase, such as factor XIII, to a composition of a temperature-sensitive gel-forming protein, such as gelatin or collagen, and incubating the composition and transglutaminase under gel-forming conditions. The resulting gels have superior strength and thermal stability, and can be used within a variety of medical and industrial applications.
    Type: Grant
    Filed: May 1, 1996
    Date of Patent: November 10, 1998
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul D. Bishop, Gerald Lasser
  • Modified factor VII
    Patent number: 5833982
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders, including platelet deposition, vascular thrombosis, ischemic reperfusion, acute closure of a coronary artery, vascular restenosis secondary to balloon angioplasty, endarterectomy, reductive atherectomy, stent placement, laser therapy or rotablation.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: November 10, 1998
    Assignees: ZymoGenetics, Inc., Novo Nordisk A/S
    Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
  • Oligonucleotide probes to L-AP4 sensitive glutamate receptor sequences
    Patent number: 5831047
    Abstract: Metabotropic receptor mGluR7 is identified and sequenced. The mGluR7 receptor subfamily mediates inhibition of transmitter release at selected glutamatergic synapses. The receptors, mGluR7-specific peptides and antibodies thereto are used to identify agonists and antagonists of G protein coupled glutamate receptor mediated neuronal transmitter release, as well as in methods of diagnosis and therapy.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: November 3, 1998
    Assignees: ZymoGenetics, Inc., State of Oregon, acting by and through the Oregon State Board of Higher Education on behalf of the Oregon Health Sciences University
    Inventors: Thomas P. Segerson, J. Mark Kinzie, Eileen R. Mulvihill, Julie A. Saugstad, Gary L. Westbrook
  • Preparation of immortalized cells
    Patent number: 5830682
    Abstract: All lines have been prepared from growth suppressor gene deficient animals. The cells include immortalized precursor cells and differentiated cells such as osteoclast precursors, osteoblast precursors, megakaryocytes, osteoclasts, osteoblasts, pancreatic .alpha.-cells, pancreatic .beta.-cells, pancreatic .delta.-cells, adipocytes, macrophages, chondrocytes, dendritic cells, hepatocytes, myocytes and prostatic cells. The cells are useful for constructing cDNA and protein libraries, screening agonists and antagonists of compounds and factors that affect metabolic pathways of specific cells and generating cell-specific antibodies.
    Type: Grant
    Filed: December 13, 1996
    Date of Patent: November 3, 1998
    Assignee: ZymoGenetics
    Inventor: Emma E. Moore
  • Materials and methods for determining ob protein in a biological sample
    Patent number: 5827734
    Abstract: Methods for determining ob protein in a biological sample are disclosed. In a preferred embodiment, the biological samples are analyzed using an ELISA capable of detecting and quantitating ob protein.
    Type: Grant
    Filed: October 4, 1995
    Date of Patent: October 27, 1998
    Assignees: University of Washington, Zymogenetics, Inc.
    Inventors: David S. Weigle, Joseph L. Kuijper, John W. Forstrom, Joyce M. Lehner
  • Modified factor VII anticoagulant proteins
    Patent number: 5824639
    Abstract: Factor VII of the coagulation cascade is modified to act as an anticoagulant. Amino acid modifications are employed to produce a modified Factor VII having a substantially reduced susceptibility to activation by enzymes which typically activate wild-type Factor VII. The modified Factor VII is able to compete with wild-type Factor VII and/or VIIa for binding tissue factor, inhibiting clotting activity. As the modified Factor VII acts specifically to interrupt the coagulation cascade, pharmaceutical compositions of modified Factor VII may be administered in place of, or in conjunction with lower doses of, conventional anticoagulant therapies.
    Type: Grant
    Filed: November 12, 1993
    Date of Patent: October 20, 1998
    Assignee: ZymoGenetics, Inc.
    Inventor: Kathleen L. Berkner
  • Modified factor VII
    Patent number: 5817788
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.
    Type: Grant
    Filed: October 24, 1994
    Date of Patent: October 6, 1998
    Assignees: ZymoGenetics, Inc., Novo Nordisk A/S
    Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
  • Hematopoietic cytokine receptor
    Patent number: 5792850
    Abstract: Novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular ligand-binding domain of a cell-surface receptor that is expressed at high levels in lymphoid tissue, including B-cells and T-cells. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo.
    Type: Grant
    Filed: May 23, 1996
    Date of Patent: August 11, 1998
    Assignee: ZymoGenetics, Inc.
    Inventors: James W. Baumgartner, Donald C. Foster, Frank J. Grant, Cindy A. Sprecher
  • Cloning and expression of human islet glutamic acid decarboxylase autoantigen
    Patent number: 5792620
    Abstract: Human pancreatic islet cell glutamic acid decarboxylase (GAD), an autoantigen involved in the development of insulin-dependent diabetes mellitus (IDDM), has been cloned, sequenced and expressed by recombinant means. Recombinant human islet cell GAD polypeptides and antibodies specific to the GAD polypeptides can be used in methods of diagnosis and treatment, including use in immunoadsorptive therapy and the induction of immune tolerance.
    Type: Grant
    Filed: August 17, 1993
    Date of Patent: August 11, 1998
    Assignees: The Board of Regents of the University of Washington, ZymoGenetics, Inc.
    Inventors: Ake Lernmark, Allan E. Karlsen, Catherine E. Grubin, William Hagopian, Patrick J. O'Hara, Donald C. Foster
  • Modified factor VII
    Patent number: 5788965
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 4, 1998
    Assignees: Novo Nordisk A/S, ZymoGenetics, Inc.
    Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
  • Recombinant production of glucagon receptors
    Patent number: 5776725
    Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding a glucagon receptor. Also provided are DNA constructs comprising a first DNA segment encoding a glucagon receptor operably linked to additional DNA segments required for the expression of the first DNA segment, as well as host cells containing such DNA constructs.
    Type: Grant
    Filed: July 1, 1993
    Date of Patent: July 7, 1998
    Assignee: ZymoGenetics, Inc.
    Inventors: Wayne R. Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, Francis J. Grant, Joseph L. Kuijper, Donald C. Foster, Si Lok, Patrick J. O'Hara
  • Glucagon receptor proteins, peptides, and antibodies
    Patent number: 5770445
    Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding a glucagon receptor. Also provided are DNA constructs comprising a first DNA segment encoding a glucagon receptor operably linked to additional DNA segments required for the expression of the first DNA segment, as well as host cells containing such DNA constructs.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: June 23, 1998
    Assignee: ZymoGenetics, Inc.
    Inventors: Wayne R. Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, Francis J. Grant, Joseph L. Kuijper, Donald C. Foster, Si Lok, Patrick J. O'Hara
  • Platelet derived growth factor gel formulation
    Patent number: 5770228
    Abstract: Therapeutic compositions comprising a therapeutically effective amount of platelet derived growth factor in a hydroxyethyl cellulose gel are provided. These compositions may include a preservative, such as methyl paraben. These compositions may also include ethanol.
    Type: Grant
    Filed: January 14, 1994
    Date of Patent: June 23, 1998
    Assignees: ZymoGenetics, Inc., Novo Nordisk A/S
    Inventors: Martin W. Edwards, Niels Christian Larsen
  • Hybrid protein C
    Patent number: 5766921
    Abstract: Human protein C molecules are modified to provide increased resistance to inactivation by human plasma factors while retaining substantially the biological activity of human protein C. The modifications are generally to the heavy chain of protein C, which chain may be substituted with a protein C heavy chain of non-human origin, such as bovine, yielding a chimeric protein C molecule. The human protein C heavy chain may also be modified to be human-like, in that at least one amino acid from a non-human sequence may be substituted for the corresponding residue(s) of the human sequence, thereby allowing the molecule to retain substantially human characteristics yet having increased resistance to inactivation. Also included are methods for producing the modified protein C molecules and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 5, 1994
    Date of Patent: June 16, 1998
    Assignee: Zymogenetics, Inc.
    Inventors: Donald C. Foster, Richard D. Holly
  • Hybrid protein C
    Patent number: 5753224
    Abstract: Human protein C molecules are modified to provide increased resistance to inactivation by human plasma factors while retaining substantially the biological activity of human protein C. The modifications are generally to the heavy chain of protein C, which chain may be substituted with a protein C heavy chain of non-human origin, such as bovine, yielding a chimeric protein C molecule. The human protein C heavy chain may also be modified to be human-like, in that at least one amino acid from a non-human sequence may be substituted for the corresponding residue(s) of the human sequence, thereby allowing the molecule to retain substantially human characteristics yet having increased resistance to inactivation. Also included are methods for producing the modified protein C molecules and pharmaceutical compositions thereof.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: May 19, 1998
    Assignee: ZymoGenetics, Inc.
    Inventors: Donald C. Foster, Richard D. Holly
  • Secretion leader trap cloning method
    Patent number: 5753462
    Abstract: Expression vectors and methods for cloning amino-terminal signal sequences are disclosed. These vectors and methods are useful tools for cloning, identifying and isolating previously unknown signal sequences. In turn, an orphan signal sequence can be used to clone, identify and isolate the corresponding orphan proteins that the orphan signal sequence directs to the surface of a cell. Using these expression vectors and methods, an orphan protein can be cloned in the absence of a functional assay that detects such protein.
    Type: Grant
    Filed: February 6, 1997
    Date of Patent: May 19, 1998
    Assignee: Zymogenetics, Inc.
    Inventor: Si Lok
  • Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
    Patent number: 5750375
    Abstract: Methods for producing secreted receptor analogs and biologically active peptide dimers are disclosed. The methods for producing secreted receptor analogs and biologically active peptide dimers utilize a DNA sequence encoding a receptor analog or a peptide requiring dimerization for biological activity joined to a dimerizing protein. The receptor analog includes a ligand-binding domain. Polypeptides comprising essentially the extracellular domain of a human PDGF receptor fused to dimerizing proteins, the portion being capable of binding human PDGF or an isoform thereof, are also disclosed. The polypeptides may be used within methods for determining the presence of and for purifying human PDGF or isoforms thereof.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 12, 1998
    Assignee: ZymoGenetics, Inc.
    Inventors: Andrzej Z. Sledziewski, Lillian Anne Bell, Wayne R. Kindsvogel